Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach
In phase II/III trials, cutaneous side effects of pazopanib were reported in less than 20% of patients, with only 1–3% being grade 3/4. We present a case of a 66-year-old man with a previous history of left nephrectomy for a stage II clear cell renal carcinoma. Approximately 18 months later, recurre...
| Հիմնական հեղինակներ: | , , , , , , |
|---|---|
| Ձևաչափ: | Հոդված |
| Լեզու: | English |
| Հրապարակվել է: |
Karger Publishers
2017-11-01
|
| Շարք: | Case Reports in Oncology |
| Խորագրեր: | |
| Առցանց հասանելիություն: | https://www.karger.com/Article/FullText/484402 |
| _version_ | 1828398157867778048 |
|---|---|
| author | Diogo Alpuim Costa Susana Baptista de Almeida Pedro Coelho Barata António Quintela Pedro Cabral Ana Afonso João Maia Silva |
| author_facet | Diogo Alpuim Costa Susana Baptista de Almeida Pedro Coelho Barata António Quintela Pedro Cabral Ana Afonso João Maia Silva |
| author_sort | Diogo Alpuim Costa |
| collection | DOAJ |
| description | In phase II/III trials, cutaneous side effects of pazopanib were reported in less than 20% of patients, with only 1–3% being grade 3/4. We present a case of a 66-year-old man with a previous history of left nephrectomy for a stage II clear cell renal carcinoma. Approximately 18 months later, recurrent disease in the lungs, mediastinum, and left psoas and bulky abdominal/pelvic nodal metastasis were documented. He was initially treated with pazopanib 800 mg q.d. and 1 week after starting this therapy, the patient presented with palpable purpura on his ankles. These lesions regressed within 2 weeks off pazopanib, but had recurred 4 weeks after he resumed medication at 400 mg q.d. Biopsy of the lesions revealed leukocytoclastic vasculitis. Despite tumour response to therapy, pazopanib was discontinued with total resolution of this skin toxicity within 2 weeks of his cutaneous toxicity. To the best of our knowledge, we report a rare yet significant cutaneous adverse reaction to pazopanib. |
| first_indexed | 2024-12-10T08:57:18Z |
| format | Article |
| id | doaj.art-7e8e5b7948a04fb8b32a4c2ce8a76ed1 |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-10T08:57:18Z |
| publishDate | 2017-11-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-7e8e5b7948a04fb8b32a4c2ce8a76ed12022-12-22T01:55:23ZengKarger PublishersCase Reports in Oncology1662-65752017-11-011031041104910.1159/000484402484402Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary ApproachDiogo Alpuim CostaSusana Baptista de AlmeidaPedro Coelho BarataAntónio QuintelaPedro CabralAna AfonsoJoão Maia SilvaIn phase II/III trials, cutaneous side effects of pazopanib were reported in less than 20% of patients, with only 1–3% being grade 3/4. We present a case of a 66-year-old man with a previous history of left nephrectomy for a stage II clear cell renal carcinoma. Approximately 18 months later, recurrent disease in the lungs, mediastinum, and left psoas and bulky abdominal/pelvic nodal metastasis were documented. He was initially treated with pazopanib 800 mg q.d. and 1 week after starting this therapy, the patient presented with palpable purpura on his ankles. These lesions regressed within 2 weeks off pazopanib, but had recurred 4 weeks after he resumed medication at 400 mg q.d. Biopsy of the lesions revealed leukocytoclastic vasculitis. Despite tumour response to therapy, pazopanib was discontinued with total resolution of this skin toxicity within 2 weeks of his cutaneous toxicity. To the best of our knowledge, we report a rare yet significant cutaneous adverse reaction to pazopanib.https://www.karger.com/Article/FullText/484402Renal cell carcinomaLeukocytoclastic vasculitisPazopanib |
| spellingShingle | Diogo Alpuim Costa Susana Baptista de Almeida Pedro Coelho Barata António Quintela Pedro Cabral Ana Afonso João Maia Silva Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach Case Reports in Oncology Renal cell carcinoma Leukocytoclastic vasculitis Pazopanib |
| title | Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach |
| title_full | Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach |
| title_fullStr | Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach |
| title_full_unstemmed | Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach |
| title_short | Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach |
| title_sort | pazopanib induced cutaneous leukocytoclastic vasculitis an exclusion diagnosis of a multidisciplinary approach |
| topic | Renal cell carcinoma Leukocytoclastic vasculitis Pazopanib |
| url | https://www.karger.com/Article/FullText/484402 |
| work_keys_str_mv | AT diogoalpuimcosta pazopanibinducedcutaneousleukocytoclasticvasculitisanexclusiondiagnosisofamultidisciplinaryapproach AT susanabaptistadealmeida pazopanibinducedcutaneousleukocytoclasticvasculitisanexclusiondiagnosisofamultidisciplinaryapproach AT pedrocoelhobarata pazopanibinducedcutaneousleukocytoclasticvasculitisanexclusiondiagnosisofamultidisciplinaryapproach AT antonioquintela pazopanibinducedcutaneousleukocytoclasticvasculitisanexclusiondiagnosisofamultidisciplinaryapproach AT pedrocabral pazopanibinducedcutaneousleukocytoclasticvasculitisanexclusiondiagnosisofamultidisciplinaryapproach AT anaafonso pazopanibinducedcutaneousleukocytoclasticvasculitisanexclusiondiagnosisofamultidisciplinaryapproach AT joaomaiasilva pazopanibinducedcutaneousleukocytoclasticvasculitisanexclusiondiagnosisofamultidisciplinaryapproach |